These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21570685)

  • 1. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline.
    West AM; Anderson JD; Meyer CH; Epstein FH; Wang H; Hagspiel KD; Berr SS; Harthun NL; DiMaria JM; Hunter JR; Christopher JM; Chew JD; Winberry GB; Kramer CM
    Atherosclerosis; 2011 Sep; 218(1):156-62. PubMed ID: 21570685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease.
    West AM; Anderson JD; Epstein FH; Meyer CH; Wang H; Hagspiel KD; Berr SS; Harthun NL; Weltman AL; Dimaria JM; Hunter JR; Christopher JM; Kramer CM
    J Am Coll Cardiol; 2011 Aug; 58(10):1068-76. PubMed ID: 21867844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
    Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
    Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.
    Fleg JL; Mete M; Howard BV; Umans JG; Roman MJ; Ratner RE; Silverman A; Galloway JM; Henderson JA; Weir MR; Wilson C; Stylianou M; Howard WJ
    J Am Coll Cardiol; 2008 Dec; 52(25):2198-205. PubMed ID: 19095139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
    Oyama K; Giugliano RP; Blazing MA; Park JG; Tershakovec AM; Sabatine MS; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2021 Oct; 78(15):1499-1507. PubMed ID: 34620406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.
    Simons L; Tonkon M; Masana L; Maccubbin D; Shah A; Lee M; Gumbiner B
    Curr Med Res Opin; 2004 Sep; 20(9):1437-45. PubMed ID: 15383192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.
    Meyers CD; Moon YS; Ghanem H; Wong ND
    Ann Pharmacother; 2006 May; 40(5):818-23. PubMed ID: 16638916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial).
    Maron DJ; Hartigan PM; Neff DR; Weintraub WS; Boden WE;
    Am J Cardiol; 2013 Jun; 111(11):1557-62. PubMed ID: 23538020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alirocumab and plaque volume, calf muscle blood flow, and walking performance in peripheral artery disease: A randomized clinical trial.
    Rrapo-Kaso E; Loffler AI; Petroni GR; Meyer CH; Walker M; Kay JR; DiMaria JM; Domanchuk K; Carr JC; McDermott MM; Kramer CM
    Vasc Med; 2023 Aug; 28(4):282-289. PubMed ID: 37093712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.
    Gagné C; Gaudet D; Bruckert E;
    Circulation; 2002 May; 105(21):2469-75. PubMed ID: 12034651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
    Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Reist C; McCagg A; Braunwald E; Califf RM
    Am Heart J; 2014 Aug; 168(2):205-12.e1. PubMed ID: 25066560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients.
    Thongtang N; Lin J; Schaefer EJ; Lowe RS; Tomassini JE; Shah AK; Tershakovec AM
    Atherosclerosis; 2012 Dec; 225(2):388-96. PubMed ID: 23040830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study.
    Hiro T; Hirayama A; Ueda Y; Komatsu S; Matsuoka H; Takayama T; Ishihara M; Hayashi T; Saito S; Kodama K;
    J Cardiol; 2014 Dec; 64(6):501-7. PubMed ID: 24725763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin.
    Hussein O; Minasian L; Itzkovich Y; Shestatski K; Solomon L; Zidan J
    Br J Clin Pharmacol; 2008 May; 65(5):637-45. PubMed ID: 18241285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.